Growth factors in prediction of adverse outcomes in first year after percutaneous interventions on coronary arteries
Abstract
The observation of 71 patients during 1 year after percutaneous coronary interventions (PCI) (58 patients without complications and 13 ones with restenosis or clinical significant stenosis in a new site) is presented in the article. Three growth factors (FGF-ß1 - fibroblast growth factor ß1; VEGF - vascular endothelial growth factor; TGF - transforming growth factor) were investigated before operation, 3, 6 and 12 months after PCI. Decrease level of FGF-ß1, TGF and increase concentration of VEGF is common in patients with CAD. The concentration of growth factors has a regular changes during 1 year after PCI with worsening abnormalities, more pronounced in patients with complications.
About the Authors
E. Y. Vasilyeva
Federal North-West Medical Research Center n.a. V. A. Almazov
Russian Federation
Russian Federation
M. A. Karpenko
Federal North-West Medical Research Center n.a. V. A. Almazov
Russian Federation
Russian Federation
E. E. Kazakova
Federal North-West Medical Research Center n.a. V. A. Almazov
Russian Federation
Russian Federation
E. A. Stabrova
Federal North-West Medical Research Center n.a. V. A. Almazov
Russian Federation
Russian Federation
T. V. Vavilova
Federal North-West Medical Research Center n.a. V. A. Almazov
Russian Federation
Russian Federation
V. V. Dorofeykov
National State University of Physical Culture, Sports and Health n.a. P.F. Lesgaft
Russian Federation
Russian Federation
References
1. Федеральная служба государственной статистики. Здравоохранение в России - 2015 г. http://www.gks.ru.
2. Kucukardali Y., Aydogdu S., Ozmen N. et al. The relationship between severity of coronary artery disease and plasma level of vascular endothelial growth factor // Cardiovasc. Revasc. Med. - 2008. - 9 (2). - 66-70.
3. Gaglia Jr M. A., Torguson R., Xue Z. et al. Insurance Type Influences the Use of Drug Eluting Stents // J. Am. Coll. Cardiol. Intv. - 2010; 3 (7): 773-779.
4. Presta M., Dell’Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast gfowth factor / fibroblast gfowth factor receptor system in angiogenesis // Cytokine and Growth Factor Reviews. - 2005. Vol. 16. - № 2. - P. 159-178.
5. Mignatti P., Rifkin D. B. Biology and biochemistry of proteinases in tumor invasion // Physiol. Rev. - 2011.- Vol. 73. - P. 161-195.
6. Klein S., Giancotti F. G., Presta M., Albelda S. A., Buck C. A., Rifkin D. B. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cell // Moi. Biol. Cell. - 2006. - Vol. 4. - P. 973-982.
7. Hansson G. K. Iflammation, atherosclerosis, and coronary artery disease // N. Engl. J. Med. - 2005. - Vol. 352, N 16. - Р. 1685-1695.
8. Doran A. C., Meller N., McNamara C. A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis // Arterioscler. Thromb. Vasc. Biol. - 2008.- Vol. 28, N 5. - P. 812-819.
9. Conway E. M., Collen D., Carmeliet P. Molecular mechanisms of blood vessel growth // Cardiovasc. Res. 2001. 49 (3). 507-521.
10. Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease. 2001, April. 30. Lazarous D. F., Scheinowitz M., Shou M. et al.
11. Flavell S. J., Hou T. Z., Lax S. et al. Fibroblasts as novel therapeutic targets in chronic inflammation // British. J. Pharmacology. 2008. Vol. 153. P. 241-246.
12. Шурыгина И. А., Шурыгин М. Г., Аюшинова Н. И., Каня О. В. Фибробласты и их роль в развитии соединительной ткани // Сибирский медицинский журнал. 2012. № 3. С. 8-12.
13. Сергеенко И. В., Семенова А. Е., Масенко В. П., Хабибуллина Л. И., Габрусенко С. А., Кухарчук В. В., Беленков Ю. Н. «Влияние реваскуляризации миокарда на динамику сосудистого эндотелиального и трансформирующего факторов роста у больных ишемической болезнью сердца // Кардиоваскулярная терапия и профилактика. - 2007. - Т. 6, № 5. - С. 12-17.
14. Vasile E., Tomita Y., Brown L. F., Kocher O., Dvorak H. F. Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/ VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J. 2001; 15 (2): 458-66.
15. Vyzantiadis T., Karagiannis A., Douma S., Harsoulis P., Vyzantiadis A., Zamboulis C. Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension // Clin. Exp. Hypertens.- 2006 Oct.- 28 (7). - Р. 603-9.
16. Belgore F., Blann A., Neil D., Ahmed A. S., Lip G. Y. Localisation of members of vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries. J Clin Pathol. 2004; 57 (3): 266-72.
17. Bhatia R. S., Tu J. V., Lee D. S. et al. Outcome of heart failure with preserved ejection fraction in a population-bused study. N England Med 2006; 255: 260-269.
Review
For citations:
Vasilyeva E.Y., Karpenko M.A., Kazakova E.E., Stabrova E.A., Vavilova T.V., Dorofeykov V.V. Growth factors in prediction of adverse outcomes in first year after percutaneous interventions on coronary arteries. Medical alphabet. 2017;1(13):20-24. (In Russ.)
Views:
242
Email this article 